News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Novartis AG, Roche’s Xolair Helps Kids With Severe Milk Allergies
March 22, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
March 21 (Bloomberg) -- Novartis AG and Roche Holding AG’s Xolair, a medication used to treat asthma attacks caused by allergens such as pollen and dust mites, helped children overcome milk allergies, a small study showed.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Novartis
MORE ON THIS TOPIC
Neurodegeneration
Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%
October 30, 2026
·
2 min read
·
Gabrielle Masson
Drug Development
Dren Bio lands $350M to push rare blood cancer therapy toward market
October 29, 2026
·
2 min read
·
Gabrielle Masson
Earnings
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
October 29, 2026
·
4 min read
·
Gabrielle Masson
Neuroscience
Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure
October 29, 2026
·
1 min read
·
Annalee Armstrong